Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus

Author(s): S.M. Cabrera, M.R. Rigby, R.G. Mirmira

Journal Name: Current Molecular Medicine

Volume 12 , Issue 10 , 2012

Become EABM
Become Reviewer
Call for Editor


Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells(Teffs) on the β cell. Recent literature now suggests that a failure of a second T cell subtype, known as regulatory T cells (Tregs), plays a critical role in the development of T1DM. During immune homeostasis, Tregs counterbalance the actions of autoreactive Teff cells, thereby participating in peripheral tolerance. An imbalance in the activity between Teff and Tregs may be crucial in the breakdown of peripheral tolerance, leading to the development of T1DM. In this review, we summarize our current understanding of Treg function in health and in T1DM, and examine the effect of experimental therapies for T1DM on Treg cell number and function in both mice and humans.

Keywords: Autoimmunity, effector T cells, regulatory T cells, Teffs, Tregs, Type 1 diabetes mellitus, autoimmune disease, hyperglycemic, phenotype, antigens, autoantigens, viral infection, cytokines, insulitis, chemokines

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 01 November, 2012
Page: [1261 - 1272]
Pages: 12
DOI: 10.2174/156652412803833634
Price: $65

Article Metrics

PDF: 17